hBVR (human biliverdin reductase) is an enzyme that reduces biliverdin (the product of haem oxygenases HO-1 and HO-2 activity) to the antioxidant bilirubin. It also functions as a kinase and as a transcription factor in the MAPK (mitogen-activated protein kinase) signalling cascade. Fluorescence correlation spectroscopy was used to investigate the mobility of hBVR in living cells and its function in the nuclear transport of haematin for induction of HO-1. In transiently transfected HeLa cells only kinase-competent hBVR translocates to the nucleus. A reduced mobility in the nucleus of haematin-treated cells suggests formation of an hBVR-haematin complex and its further association with large nuclear components. The binding of haematin is specific, with the formation of a 1:1 molar complex, and the C-terminal 7-residue fragment KYCCSRK 296 of hBVR contributes to the binding. The following data suggest formation of dynamic complexes of hBVR-haematin with chromatin: (i) the reduction of hBVR mobility in the presence of haematin is greater in heterochromatic regions than in euchromatic domains and (ii) hBVR mobility is not retarded by haematin in nuclear lysates that contain only soluble factors. Moreover, hBVR kinase activity is stimulated in the presence of double-stranded DNA fragments corresponding to HO-1 antioxidant and HREs (hypoxia response elements), as well as by haematin. Experiments with nuclear localization, export signal mutants and si-hBVR [siRNA (small interfering RNA) specific to hBVR] indicate that nuclear localization of hBVR is required for induction of HO-1 by haematin. Because gene regulation is energy-dependent and haematin regulates gene expression, our data suggest that hBVR functions as an essential component of the regulatory mechanisms for haem-responsive transcriptional activation.
INTRODUCTION
BVR-A (biliverdin reductase A) is an evolutionarily conserved enzyme [1] that catalyses the reduction of biliverdin IXα, the product of the catalytic activity of the HO (haem oxygenase) enzymes HO-1 and HO-2, to the quencher of free radicals, bilirubin [2] [3] [4] [5] . Free radical-mediated oxidative stress is implicated in the aetiology of a wide spectrum of pathophysiological conditions [6, 7] . The second form, BVR-B, is predominantly expressed in fetal tissue [8] . The reductase is unique among biological catalysts in having a dual pH/cofactordependent activity profile [9] ; either NADPH or NADH are used, with pH optima of 8.7 and 7.0 respectively. BVR is present across metazoan species and its homologue is found in unicellular cyanobacteria [1] .
The human protein is a 296-residue soluble protein (295 residues in the rat protein) that in the past was known to be localized only in the cytoplasm and recognized only for its reductase capacity. More recently, however, the protein was detected in the nucleus [10] in the fixed tissue of animals exposed to cytokines and free radical inducers of HO-1, and the enzyme was characterized as a transcription factor and a dual-specificity (serine/threonine/tyrosine) kinase. The human enzyme was shown, under strictly Mn 2+ -dependent conditions, to autophosphorylate several serine, at least one threonine and two of its six tyrosine residues [11] . IRS-1 (insulin receptor substrate 1), PKC-βII (protein kinase C βII) and HO-2 were identified among the substrates for its serine/threonine kinase activity [11, 12] , while PKC-ζ was found to be activated by the enzyme [13] . The kinase activity of hBVR (human BVR) was demonstrated to be stimulated by H 2 O 2, insulin, sodium arsenite and the metalloporphyrin Co-PP (cobalt protoporphyrin) [11, 14] . Activation by hBVR of oxidative stressresponsive transcription factors in the MAPK (mitogen-activated protein kinase) pathways that are involved in the regulation of HO-1, including c-Jun, c-Fos, ATF2 (activating transcription factor 2) and CREB (cAMP-response-element-binding protein), as well as NF-κB (nuclear factor κB), were uncovered [14] [15] [16] [17] [18] [19] [20] . The multiplicity of functions ascribed to hBVR reflects its primary and predicted secondary structural features. The predicted primary sequence of rat and human BVR and the crystal structures of the rat BVR-cofactor complex [21] [22] [23] permit dividing hBVR into two domains: the N-terminal catalytic/nucleotide-binding domain with a preponderance of hydrophobic and charged residues, and the C-terminal regulatory domain [24, 25] . This latter domain, as predicted by the crystal structures of rat BVR, contains six strands that form a large β sheet, an ideal interface for protein-protein interactions [22, 23] . The C-terminus of the protein is cysteine-rich and contains
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Developments in live-cell imaging have allowed investigations into the localization and mobility of different intracellular proteins to reveal their specific molecular mechanisms. The discovery and development of genetically-encoded fluorescent proteins allows direct monitoring of the behaviour of proteins in their physiological context in living cells [29] . Among the available techniques, FCS (fluorescent correlation spectroscopy), which is non-invasive, is considered best suited for the study of molecular mobility, transport and diffusion in living cells [29, 30] . In FCS, low probe concentrations and laser powers are required, thus minimizing the perturbation of the biological system. FCS has been used to determine the diffusion coefficients of different sized DNA molecules in living cells, crowded solutions, cytosol extracts and artificial actin networks [31] . Moreover, FCS offers the opportunity to investigate different aspects of intra-and intercellular communication in vivo and in real time. Among the multitude of applications of FCS are investigations on DNA structure and interactions [32] , protein structure, interaction and function [33] [34] [35] , ligand-receptor binding and diffusion [36] .
In the current study, FCS was used to assess the mobility of hBVR in living HeLa human cervical carcinoma cells under treated and control conditions and to determine whether kinase activity of hBVR plays a central role in its nuclear trafficking. Nuclear transport of haematin was used to gain insight into hBVR function in the nucleus. The noted features and current gathered data are consistent with the potential function of hBVR to serve as a conveyer of haem from the cytoplasm to the nucleus for regulation of gene expression. The haem molecule is a regulator of gene expression, including that of HO-1 and ALA synthase I (aminolevulinate synthase I), the rate-limiting enzymes in haem degradation and biosynthesis respectively. In turn, haem is essential for the synthesis and function of haemoproteins, including NOS, soluble guanylate cyclase, cytP450 enzymes and respiratory cytochromes [37] [38] [39] . Data presented in this study identify hBVR as a haem-binding and haem-transport kinase, and suggest its role in the modulation of haem-regulated gene expression.
MATERIALS AND METHODS

Materials
8Br-cGMP and SS (salmon sperm) DNA were purchased from Sigma. Haemin chloride (Fe-protoporphyrin IX) was a product of Porphyrin Products (Logan, UT, U.S.A. 
Expression vectors
hBVR and the mutants G17A and C281A/C292A/C293A were expressed in Escherichia coli using the pGEX 4T-2 plasmid as described previously [11] , and the fusion protein was collected on GSH beads. To cleave the tag, the preparation was treated with thrombin (Amersham Biosciences). Depending on the experiment, the cleaved preparation or GST-tagged protein was used. Mutations in the EGFP (enhanced green fluorescent protein)-FLAG-hBVR fusion construct were introduced by sitedirected mutagenesis. The candidate nuclear localization signal, GLKRNR (residues 222-227), was mutated to AIGSTG, while the candidate nuclear export signal, LVSLFGELSL (residues 176-185), was changed to AVSVFGEVSA.
Cell culture and transient transfection assays
HeLa cells were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % FBS (fetal bovine serum) at 37
• C, with 5 % CO 2 in a humidified atmosphere. Penicillin and streptomycin were included at 100 units/ml and 100 μg/ml respectively. Cells were seeded one day prior to transfection in 8-well LabTek chambered coverglass cuvettes. Transfection of HeLa cells was performed at ∼ 80 % confluency using Lipofectamine 2000 reagent (Invitrogen) following the manufacturer's instructions. The cells were washed with OptiMem (Invitrogen) before measurement to eliminate background fluorescence due to Phenol Red in the medium that would interfere with FCS. Ligands were added 1 h before starting the FCS measurements. Haematin and 8Br-cGMP were used at final concentrations of 10 μM and 50 μM respectively.
FCS experiments
For FCS experiments, transfections were performed in 8-well chambered coverglasses with 100 ng of vector per cm 2 of cell culture plate. Theoretical and mathematical details of the FCS method are provided in the Supplementary Data, at http:// www.BiochemJ.org/bj/413/bj4130405add.htm. Measurements were performed on a commercial LSM510 ConfoCor2 combination system at room temperature (∼ 21
• C). The images were collected using a LSM 510 laser scanning confocal microscope (Carl Zeiss, Jena, Germany) with a 20 mW argon ion laser and a 40× Plan-Apochromat water-immersion objective. Briefly, the 488 nm line of an argon-ion laser was focused through a Zeiss C-Apochromat 40×, NA 1.2 water-immersion objective, and the fluorescence emission was recorded between 505 and 550 nm using an avalanche photodiode. Fluorescence intensity fluctuations were recorded at different spots in each cell (cytoplasm and nucleus). At each spot, measurements were performed over 20 s and repeated 10 times. On average, 10 cells per condition were analysed. Using the Origin software, the autocorrelation curves from the living cells measurements were fitted to an anomalous diffusion model to derive the translational diffusion time through the confocal volume. The apparent diffusion coefficients obtained for each curve were then averaged.
For the experiments performed in nuclear extracts where the nucleoplasm was highly diluted, the anomalous diffusion model gave an anomalous parameter α = 1, indicating free diffusion. FCS measurements in these conditions were best fitted with a single component model.
Nuclear extracts
HeLa cells were transfected in 6-well plates. At 36 h posttransfection, cells were washed with PBS, harvested, and centrifuged. The pellet was lysed in 400 μl of hypo-osmotic buffer [10 mM Tris/HCl, pH 7.8, 10 mM NaCl, 0.5 mM DTT (dithiothreitol), 1 × PIC (protease inhibitor cocktail) and 0.2 mM PMSF] with a Dounce homogenizer. Nuclei were then isolated by centrifugation at 10 000 g for 5 min at 4
• C and lysed in 50 μl of hyper-osmotic buffer (50 mM Tris/HCl, pH 7.4, 400 mM KCl, 1 mM EDTA, 0.1 % Triton X-100, 10 % glycerol, 1 × PIC and 0.2 mM PMSF). After centrifugation, the supernatant was diluted with 3 volumes of 50 mM Tris/HCl, 1 mM EDTA, 10 % glycerol, 1 × PIC and 0.2 mM PMSF to bring the salt concentration to 100 mM. Nuclear extracts were stored at −20
• C and incubated with haematin for 1 h at 4
• C before FCS.
Spectroscopy methods
Spectra were recorded using an Aminco DW2 spectrophotometer with an OLIS upgrade. Haematin solution (50 mM) was freshly prepared in a 1:1 (v/v) mixture of 1 M NaOH and methanol, and further diluted to a 500 μM concentration using 100 mM Tris/HCl (pH 7.5) with 0.01 % Tween 20 [26] . For further dilution, as required, the same buffer was used. Binding of haematin to hBVR was assessed using a procedure similar to that used previously [27] ; difference spectra for GST-hBVR plus haematin compared with haematin alone, at molar ratios of haematin/hBVR as indicated in the appropriate Figures, were recorded between 350 and 650 nm. The difference in absorbance between 414 nm and 606 nm was measured and used to titrate binding. The data were fitted by regression analysis using Graphpad Prism 3.0 software. Haematin/hBVR sequence-based peptide (KKRILHC 281 and KYCCSRK 296 ) interaction was assessed by a shift in the Soret absorbance band of haematin in the presence of the peptide [26] . Peptides were added incrementally to a 5 μM haem solution, beginning with a 1:1 molar ratio, and the spectrum was recorded between 350 and 650 nm. Peptides were also added to the reference cuvette, although neither peptide showed any absorbance in this range. In the experiment testing competition between peptide and KCN for haematin binding, KCN (from a freshly prepared 500 mM stock solution) was added in increments to a solution of 20 μM peptide KYCCSRK 296 and 5 μM haematin, with the spectrum being recorded after each addition.
hBVR kinase activity
Oligonucleotides (20 μM) containing either an ARE (antioxidant response element) [40] : 5 -AGCTGCATTTCTGCTGCG-TCATGTTTGGGAGG-3 or HRE (hypoxia response element) [41] : 5 -GATCGCCCTACGTGCTGTCTCAGATC-3 , and their complements were annealed in 100 mM NaCl by slow cooling from 85
• C. hBVR autophosphorylation was assayed using the kinase assay described previously [11] in the presence of nucleic acids or haematin prepared as above. Purified recombinant hBVR (1.6 μM) was incubated for 10 min in 50 μl kinase assay buffer (50 mM Hepes, pH 8.4, 30 mM MnCl 2 and 0.2 mM DTT) with 2 μM oligonucleotide (ARE or HRE) or 100 μg/ml SS DNA. The reaction was started by the addition of 10 μM ATP plus 10 μCi [γ -
32 P]ATP, incubated for 1 h at 30
• C, and terminated with the addition of Laemmli sample buffer. The samples were run on 8 % gels, transferred to PVDF and autoradiographed. hBVR kinase activity was assessed in kinase assay buffer using 10 μM MBP as the substrate. The reaction was initiated as above. Haematin (10 or 50 μM) was added 10 min prior to the addition of ATP. The reaction was carried out in the dark, and was terminated with the addition of an equal volume of 10 % phosphoric acid and an aliquot was directly transferred to P81 Whatman filters, washed in 0.75 % phosphoric acid (5×) and counted in a Beckman liquid scintillation counter.
RT-PCR (reverse transcription-PCR) experiments
Cells in 6-well plates were transfected with pcDNA3-hBVR, mutants or an empty pcDNA3 vector. After DNA addition, the cells were allowed to recover for 4 h in DMEM containing 10 % FBS for 2 h. Cells were serum-starved for 1 h, then treated with 10 μM haematin for 30 min. The medium was replaced with DMEM containing 10 % FBS and incubation was continued. Cells were harvested 2 and 6 h after the last medium change. Untreated cells were used as a control -these were subjected to all medium changes, except for the addition of haematin. Cells were also treated with si-hBVR [siRNA (small interfering RNA) specific to hBVR] [14] or its scrambled form [13] 7 h and 3.5 h prior to haematin treatment for 30 min. The medium was replaced with DMEM containing 10 % FBS and including si-hBVR [or sc-BVR (scrambled RNA form of si-hBVR)], if appropriate. Cells were harvested 2 and 6 h after the last medium change; a further addition of si-hBVR or sc-BVR was made after 3 h.
Cells were lysed by the addition of TRIzol reagent. RNA was purified from lysates as described by the manufacturer. Total RNA (2.5 μg) was used as a template for cDNA synthesis using Superscript II. The cDNA was used as a template for PCR, using the gene-specific primers noted below and Taq polymerase. Reactions included two sets of primers -HO-1 (HO-1f: CCCAG-CACCGGCCGGATG; HO-1r: GCCAGAGCTGGGCAGGTC-CAG) was amplified together with β-actin (actin-f: GTGC-TACGTCGCCCTGGAC; actin-r: CTAGAAGCATTTGCGGTG-GAC), and hBVR (hBVRf: CTGTGGGAGCTGGCTGAGCAG; hBVRr: TTACTTCCTTGAACAGCAATATTTCTG) was amplified together with GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (GAPDH-f: AAGGTCGGAGTCAACGGATTT-GGT; GAPDH-r: TGCAGGAGGCATTGCTGATGATCT). Reaction conditions (annealing temperature and number of cycles) were adjusted for the sequences being amplified. Reaction products were resolved by gel electrophoresis, photographed on an imaging system, and signals integrated. Specific signals were normalized on β-actin or GAPDH as appropriate.
RESULTS
EGFP-BVR is localized in both the cytoplasm and nucleus, and exhibits a diffuse distribution
HeLa cells were transiently transfected with expression vectors for EGFP-hBVR. This allowed for examination of the pattern of distribution of the green fluorescent proteins by confocal imaging ( Figure 1 ). As shown in Figure 1(a) , the wild-type protein is present in both the cytoplasmic and nuclear compartments, whereas it is excluded from the nucleoli. To investigate further a possible change in cellular localization and the pattern of expression of hBVR in response to stimulation with ligands, HeLa cells were transfected with EGFP-tagged wt hBVR (wild-type hBVR) treated with haematin (10 μM) or 8Br-cGMP (50 μM), and used for image collection (Figures 1b and 1c) . Haematin and 8Br-cGMP were added 1 h before the start of the FCS experiments. The images obtained showed that as with wt hBVR, in the presence of the ligands the protein was distributed between the nucleus and cytoplasm and excluded from the nucleolus. In all cases, the protein in both compartments displayed a diffuse staining pattern.
FCS study of hBVR mobility in diffuse stained cells
FCS was used to determine the mobility of hBVR, and the effect of ligands on mobility of the protein in transiently transfected HeLa cells. The experiments were performed in areas with a diffuse expression pattern, meaning that only cells with low expression levels (nanomolar range, as can be estimated from the number of molecules in the ∼ 1 μm 3 , i.e. 1 fL, spot) were selected for the FCS experiments.
The FCS measurements were performed over 20 s in each spot selected in the cell and the autocorrelation curves obtained from the analysis of fluctuations of fluorescence intensity due to the diffusion of fluorescent molecules through the confocal volume were fitted with an anomalous diffusion model (Supplementary Figure S1 , at http://www.BiochemJ.org/bj/413/ bj4130405add.htm). Applying this model to hBVR diffusion in the cytoplasm and the nucleus showed high mobility of the protein in both compartments ( Table 1) . As a control for the hBVR FCS experiments, the mobility of EGFP alone was studied in the cytoplasm and nucleus of HeLa cells.
The diffusion coefficients calculated from the resulting average diffusion times show that the diffusion of EGFP-hBVR is rapid in both compartments, and that the protein is not immobilized ( Table 1 ). The addition of 8Br-cGMP did not influence the mobility of the protein in either the cytoplasm or the nucleus. Interestingly, while haematin addition to wt hBVR did not influence the protein mobility in the cytoplasm, it significantly reduced the mobility in the nucleus from 12 + − 0.6 μm 2 /s to 4.5 + − 0.2 μm 2 /s (Table 1) . When assessed quantitatively, the treat- ment with either haematin or 8Br-cGMP resulted in a preferential distribution of hBVR into the nucleus (Figure 2) as evidenced by the ratio of the number of hBVR particles in the nucleus to the number in the cytosol. It is noteworthy that although in the presence of 8Br-cGMP the mobility of nuclear EGFP-hBVR was not reduced, there is still a significant increase of EGFP-hBVR in the nucleus when this ligand is added. However, this effect is less pronounced in comparison with haematin.
In vitro evidence of haematin interaction with hBVR
The results of the hBVR mobility analysis in the nuclei of living cells (Figure 2 ) revealed an apparent reduction of mobility in the presence of haematin, suggesting haematin-hBVR interactions.
In order to characterize this phenomenon further, additional in vitro experiments to examine hBVR-haematin interactions were performed.
In preliminary experiments, it was noted that addition of an equimolar amount of hBVR to a solution of haematin resulted in an altered haematin absorbance spectrum. Because hBVR purified from E. coli does not display absorbance in the visible spectrum in the range of 350 and 650 nm, the change in spectrum in the presence of haematin was surmised to be indicative of haematin binding to hBVR. Those observations were further extended and the results are shown (Figure 3 ). Addition of a GST-hBVR fusion protein to a solution of haematin resulted in a shift in the absorbance spectrum. The difference spectra of haematin in the presence or absence of GST-hBVR are presented in Figure 3(a) . Haematin solutions of different concentrations were examined in the presence of a constant concentration of GST-hBVR. Incremental increases in absorbance were observed up to a 1:1 ratio of haematin to protein, after which there was an apparent discontinuity, such that further addition was ineffective, until ratios exceeding 1.5:1 were achieved. While the data shown are for GST-hBVR, it was noted that identical results were seen with purified hBVR lacking GST. These data were used to titrate haematin binding to hBVR [27] . At each haematin:protein ratio, the absorbance at 414 nm was determined from difference spectra as in Figure 3(a) . The data for two independent experiments are plotted in Figure 3(b) ; linear regression of the data for haematin to protein ratios 1:1 yield a slope that is not statistically different from zero, whereas there is a clear increase up to an approx. 1:1 ratio. The lines intersect at a ratio of 0.93:1, suggesting that each molecule of hBVR is able to bind one molecule of haem.
An hBVR peptide binds haematin
We had reason to suspect the involvement of the C-terminal cysteine-rich domain of hBVR in haematin binding. Cysteine and histidine are candidates for haem iron binding and two 7-residue peptides from this region of the protein have been shown to modulate the activity of PKC-ζ [13] . The peptide KKRILHC (residues 275-281) is a potent inhibitor of the activity of this kinase, while the peptide KYCCSRK (residues 290-296) activates the enzyme. We have previously demonstrated that short peptides containing a HRM with the cysteine-proline core dipeptide of HO-2 bind haematin, and the cysteine residue is the haem iron ligand [26] . The same approach was applied here. The peptides were added to a haematin solution at pH 9, in a 4-fold molar excess. There was no discernable change in colour for KKRILHC, whereas the addition of KYCCSRK resulted in a change to a deep reddish brown ( Figure 4A ). The apparent inability of the KKRILHC peptide to alter the haematin color may be a consequence of the position of the cysteine residue at the end of the peptide, where it may be a less effective ligand for haem iron, as opposed to the more central location(s) in KYCCSRK. The binding affinities of two CPF sequences in the HO-2 HRM are dependent on the nature of their flanking residues [26] . For comparison, a solution of GST-hBVR fusion with haematin is also shown in the panel. These observations were demonstrated more rigorously by examination of the haematin spectrum in the presence of peptides. A 4-fold molar excess of KYCCSRK produced changes in the visible spectrum; the Soret band shifted to a shorter wavelength, and this peak also became broader ( Figure 4B ). The α and β bands at longer wavelengths were lost (inset, Figure 4B ). Taken together, the data of Figures 4(A) and 4(B) indicate that haematin is bound by the peptide. On the other hand, the addition of KKRILHC did not affect the spectrum ( Figure 4C ) which is consistent with the data shown in Figure 4(A) . Two other peptides, KYCCSRA and KFCCSRK, related to the haematin-binding hBVR peptide, were also examined ( Figures 4D and 4E ). Both peptides produced the same spectrum changes as seen for KYCCSRK, suggesting that both bind haematin, and further, that neither the tyrosine nor Cterminal lysine residues are involved in binding. In this respect, the KYCCSRA peptide behaves differently in haematin binding from what it does with respect to PKC-ζ activity, where, unlike its parent molecule, it is ineffective in activating the kinase.
Binding of haematin to the peptide KYCCSRK is dosedependent ( Figure 5A ). The shift in the Soret peak is first seen after the addition of an equimolar amount of peptide. Continued addition led to a complete change after addition of a 4-fold excess and further addition did not alter the spectrum. Similar changes were seen for the α and β bands ( Figure 5A, inset) .
Figure 4 The C-terminal peptide of hBVR interacts with haematin
(A) In the left-hand photo, an equal volume of 2 mM peptide was added to 400 μM haematin, in 100 mM Tris/HCl (pH 9), 75 mM NaCl and 0.01 % Tween 20. For the sample labelled haematin, buffer only was added. For comparison, a sample containing 40 μM haematin and 10 μM GST-hBVR in the same buffer is also shown in the right-hand photo. (B) The spectrum of a 5 μM haematin solution, in 100 mM Tris/HCl (pH 7.5) and 0.01 % Tween 20, was determined (with buffer alone in the reference cuvette, spectrum a), after which a 4-fold molar excess of the peptide KYCCSRK (hBVR aa290-296) was added to each cuvette, and the spectrum was determined again (spectrum b). (C-E) Spectra were measured as in (B), except that the peptides KKRILHC (hBVR aa275-281), KYCCSRA or KFCCSRK respectively were used. The insets show magnified absorbance at longer wavelengths.
The affinity of binding was examined by conversion into the cyanide haemochromogen ( Figure 5B ). Incremental addition of KCN to the KYCCSRK-haematin complex resulted in a shift in the Soret peak from the short-wavelength characteristic of the complex to that of the cyanide haemochromogen. These data enabled determination of the equilibrium constant for the reaction haem:peptide → haem:CN, yielding a value of K = 2.4 × 10 −7 , which suggests that the BVR peptide binds haematin less strongly than cysteine-containing peptides from HO-2, which yielded values for K < 10 −10 [26] .
Impaired nuclear mobility in haematin-treated cells requires kinase-competent hBVR
To investigate further the mobility of hBVR, two hBVR mutants defective either for ATP binding (G17A mutant) or for protein-protein-dependent interaction and/or haematin binding were generated. Specifically, mutations were introduced in the N-terminal ATP binding/kinase domain (GXG 17 XXG) and the Cterminal cysteine-rich motif (HC 281 X 10 C 292 C 293 ). HeLa cells were transfected with expression vectors for EGFP-wt hBVR, G17A or the C281A/C292A/C293A mutant in the absence or presence of ligands, haematin and 8Br-cGMP, and the mobility was studied by FCS in living HeLa cells ( Figure 6 and Table 2 ). The FCS data reveal that the EGFP-BVR G17A mutant exhibits nearly similar diffusion coefficients to the wild-type protein, and that treatment with 8Br-cGMP did not affect the mobility of the mutant protein in either the cytoplasm or nucleus (Table 2) . Interestingly, the effect of haematin on the mobility of the wild-type protein in the nucleus was abolished for this mutant. Instead, a remarkable change in the pattern of hBVR distribution was observed after haematin stimulation, with a punctate appearance in the cytoplasm and a decreased concentration in the nucleus compared with (A) The spectrum of a 5 μM solution of haematin, in 100 mM Tris (pH 7.5) and 0.01 % Tween 20, was measured. The peptide KYCCSRK was incrementally added to the sample and reference cuvettes and the difference spectrum was recorded after each addition. The haematin spectrum is labelled a, whereas spectra b-g have 5, 10, 15, 20, 25 or 30 μM peptide added respectively. (B) 10 mM KYCCSRK was added incrementally to 5 μM haematin until a complete shift in the Soret peak was achieved -the reference cuvette was adjusted to the same peptide concentration. Freshly prepared 0.5 mM KCN was then added incrementally, and the spectrum recorded after each addition. The insets show the spectra between 500 and 650 nm at an expanded scale. Spectrum a is that of haematin with 30 μM peptide; spectra b-l are after the addition of 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5 and 25 mM KCN respectively.
8Br-cGMP-stimulated cells. As protein mobility in a cellular compartment can be an energy-dependent process, the fact that the mobility of the EGFP-BVR G17A mutant is not altered upon adding haematin is most likely due to the inability of this mutant to bind ATP. In the case of the EGFP-hBVR C281A/C292A/C293A mutant, the pattern of distribution of the protein and its mobility were similar to those of the wild-type protein in the absence of ligand, and are not affected by 8Br-cGMP stimulation (Figure 6 Table 2 The diffusion coefficients of EGFP-hBVR G17A and C281A/C292A/ C293A mutants obtained in living cells HeLa cells were transiently transfected with the expression vector for EGFP-hBVR mutant constructs. The mobility of the fluorescent protein was analysed in the cytoplasm and nucleus. Autocorrelation curves were fitted with the Origin software as in Table 1 . and Table 2 ). However, as noted, although there is a significant decrease in mobility of the haematin-bound mutant hBVR in the nucleus, the diffusion constant is 50 % higher compared with that of wt hBVR after haematin treatment. This observation is consistent with the data shown in Figure 5 that suggest involvement of cysteine residues in the KYCCSRK peptide in haematin binding. However, the fact that in the presence of haematin diffusion in the nucleus was nonetheless slowed down evoked the possibility that other potential haem ligands, including His 280 , which flanks Cys 281 , Cys 74 or Cys 204 might also participate in haem binding.
BVR diffusion in heterochromatic regions and in nuclear lysates reveals an interaction with DNA in the presence of haematin
The reduced mobility of hBVR in the nucleus upon haematin treatment suggested an interaction with large complexes of proteins or transient interactions with rather immobile components of the nucleus, such as chromatin. This possibility of an hBVRchromatin interaction was examined by applying a model of threedimensional genome scanning which was recently proposed for several proteins that act as transcription factors [42] and depicts non-specific and transient interactions with chromatin. We reasoned that if hBVR is interacting with chromatin in the presence of haematin, this would imply that hBVR can scan chromatin, transiently interacting with non-specific binding sites through its DNA-binding domain. In this case, hBVR mobility in the presence of haematin should be affected mainly in regions where chromatin is dense and hence where the concentration of potential binding sites is high. To visualize chromatin density in living cells, HeLa cells were co-transfected with EGFP-hBVR and mRFP (monomeric red fluorescent protein)-tagged histone H2B ( Figure 7) ; mRFP intensity is directly linked to chromatin concentration, enabling discrimination between hetero-and euchromatin [43] . Although both in the absence and presence of haematin EGFP-BVR diffuses on average more slowly in regions of higher chromatin density (Figure 7b ), a dramatic reduction in hBVR mobility was observed in heterochromatic regions in the presence of haematin, suggesting an interaction of hBVR with chromatin. Also, the anomalous parameter was decreased in these Table 3 Haematin does not reduce the mobility of the EGFP-hBVR in the nuclear extract devoid of chromatin HeLa cells were transiently transfected with the expression vector for EGFP-wt hBVR, the chromatin-depleted nuclear extract was prepared as described in the text and the mobility of the fluorescent protein in the extract was analysed. Autocorrelation curves were fitted with the Origin software to a free diffusion (one-component) model to derive the translational diffusion time through the confocal volume. areas, reflecting the change in interactions with the environment (results not shown). To test whether chromatin plays a role in the lower mobility of hBVR in the nuclei in the presence of haematin, the mobility of wt hBVR in nuclear extracts, where only soluble factors are present, was measured. Interestingly, the effect of haematin observed in living cells is abolished for the nuclear extracts ( Table 3 ), suggesting that the lower mobility of hBVR in the living cells upon adding haematin is due mainly to interactions with chromatin. Taken together, these findings suggest that the binding of hBVR to selective regions of chromatin causes structural/functional changes that affect its functions in the nucleus, including transcriptional and kinase activities.
Inhibition of hBVR nuclear transport inhibits haem-dependent HO-1 gene transcription
If, as we postulated, haematin is binding to hBVR and being transported to the nucleus, with a subsequent reduction in mobility of the protein, it might be expected that interfering with the transport of hBVR into the nucleus after treatment of cells with haematin would inhibit the ability of haematin to activate gene expression. For this purpose, transcription of the HO-1 gene in cells transfected with a wt hBVR expression construct, and in parallel cultures transfected with NLS or NES hBVR mutants was examined. Transport of haematin to the nucleus by hBVR would enable its delivery to the transcriptional repressor Bach1, which, on binding haematin dissociates from the DNA and is replaced by the Nrf2 transcription factor [44, 45] . While haematin treatment of cells transfected with wt hBVR plasmid activated HO-1, the haematin effect was significantly reduced when cells were transfected with NLS or NES mutants or an empty plasmid (Figure 8a) . Mutation of the NLS signal in hBVR would be expected to impair the delivery of the protein-bound haematin to the nucleus, whereas the NES mutant would accumulate in the nucleus.
To further examine the role of hBVR in induction of HO-1, we reasoned that reduction in the total hBVR content of the cell using siRNA should impair HO-1 gene expression in response to haematin treatment. In comparison to cells treated with a control siRNA, in which the hBVR-specific sequence was scrambled (sc-BVR), or to uninfected cells, cells pretreated with si-hBVR [14] for 7 h prior to addition of haematin showed a significant reduction of HO-1 induction (Figure 8b) . Collectively, the data shown in Figures 8(a) and 8(b) reveal that, when normal nuclear trafficking of hBVR is prevented or the overall level of protein in the cell is reduced, induction of HO-1 by haematin is attenuated.
Previous studies had suggested that phosphorylation of hBVR is essential for its DNA binding [14] . Therefore we examined further whether addition of DNA to purified hBVR might affect its kinase activity. As shown in Figure 8 (c), incubation of hBVR with a double-stranded oligonucleotide containing either an ARE or HRE consensus sequence resulted in enhanced autophosphorylation of the protein when compared to the protein alone. Denatured DNA from SS, on the other hand, appears to inhibit the activity, suggesting that hBVR may interact with single-stranded DNA differently.
In the subsequent experiment, we examined the effect of haematin on the kinase activity of hBVR. Preincubation of hBVR with haematin resulted in an up to 2-fold activation of kinase activity, at a concentration of 50 μM (Figure 8d ) -lower concentrations also enhance activity, albeit to a lesser extent. Thus conditions that result in the reduced mobility of hBVR in the nucleus also result in increased kinase activity of the protein, suggesting that this function of the protein is of paramount importance in the nucleus, in the context of its mobility and chromatin binding.
DISCUSSION
To test the possibility of hBVR functioning as a haem transporter, the present study involving imaging hBVR in the living cell was undertaken. Trafficking of distinct proteins among intracellular compartments and to and from the cell membrane mediates cell signalling and the transport of gene regulatory stimuli. However, understanding protein behaviour, localization, trafficking and participation in complexes in living cells are among the challenges in cell biology. In this study, advantage was taken of advanced confocal microscopy combined with the use of fluorescent fusion proteins to investigate the localization and mobility of hBVR in the absence and presence of haematin and cGMP, and to explore its potential functions in the transport of haematin and the regulation of gene expression. The present investigation has identified the function of hBVR as a cytoplasmic-nuclear transporter of haematin. And expression of HO-1, which was used as the prototype for haem-regulated genes, was shown to be influenced by nuclear transport of hBVR. Although the metalloporphyrin complex is a commonly-known regulator of genes that control cell respiration, energy production and respond to changes in the oxidation status of the cellular milieu, prior to this study its cellular transporter was not identified. In the past, it was generally assumed that hBVR is localized exclusively in the cytosol. The images of living cells obtained here show that in cells that have recently undergone mitosis the protein is, for the most part nuclear-localized, allowing the evaluation of its mobility in the nucleus of haematin-treated cells.
FCS, a technique with microsecond resolution that has been highly satisfactory in measuring the diffusion of different proteins in living cells [33] , proved useful in the elucidation of nuclear mobility and its potential function in the nucleus. The environment of living cells is crowded, especially in the nucleus, which contains structural networks such as chromatin and the nuclear matrix, and elevated protein concentrations [46] . The model of anomalous diffusion and application of correction factors compensate for steric hindrance or binding events that can alter the free diffusion process [47] . When the anomalous diffusion model was applied to the movement of hBVR in living cells, the result was an improvement in accuracy of the autocorrelation fits. The validity of this approach was confirmed by the observation that the anomaly parameter was always smaller than one, reflecting the complexity of the cellular environment. An interesting result from the FCS data is that un-liganded (free) wt hBVR has a diffusion coefficient that reflects a high mobility of the protein in both the cytoplasm and nucleus (Table 1) . Assessment of hBVR mobility in living cells in the presence of 8Br-cGMP revealed that mobility of hBVR was not reduced in the cytoplasm or nucleus upon addition of the ligand. However, although stimulation with haematin did not affect mobility of the protein in the cytoplasm, it caused a remarkable decrease in its nuclear mobility ( Table 1) .
The reduced mobility of the protein in the nucleus is probably due to its interaction with slow moving nuclear components, with chromatin being the most likely candidate. The suggested interaction of hBVR with chromatin is consistent with its demonstrated binding in a dimeric complex to a DNA fragment from the HO-1 promoter containing two AP-1 (activator protein 1) sites in vitro [14, 28] , and induction of HO-1 mRNA and ATF-2/CREB mRNA in cells infected with Ad-hBVR (adenoviral hBVR) [16] . Based on reported quantitative FRAP (fluorescence recovery after photobleaching) studies, a high proportion of transcription factors transiently interact with specific and nonspecific sites on chromatin [42, 48, 49] and the interaction greatly affects the diffusion of the proteins; the proteins are essentially performing a 'three-dimensional genome scanning' until they reach binding sites at their target genes [42] .
By using H2B-mRFP to visualize the state of chromatin, a markedly altered mobility of hBVR in heterochromatic regions in the presence of haematin was observed, which suggests an enhanced hBVR-chromatin interaction in the dense chromatin regions. This interpretation is consistent with the FCS results that show that the haematin-mediated reduction in hBVR mobility observed in the living cells was abolished in nuclear extracts devoid of chromatin material. The fact that the measured diffusion coefficient of EGFP-hBVR (19.2-22.2 μm 2 /s) in lysates of known viscosity was substantially lower than the value of 38 μm 2 /s calculated for the monomer in the same medium suggests interaction with other soluble proteins. Accordingly, the possibility that hBVR interaction with chromatin is an event mediated and/or enhanced by the soluble cofactors is rather likely. Both types of interactions, hBVR-chromatin and proteinprotein, are likely to be involved in the function of hBVR in the regulation of oxidative stress-inducible gene expression and the currently observed induction of HO-1 by haematin. Binding of hBVR to regulatory elements would orchestrate recruitment of transcriptional machinery to the promoter region of oxidative stress-responsive genes. In this context, the present findings that ARE-or HRE-containing oligonucleotides stimulate hBVR kinase activity may suggest participation of hBVR in the recruitment of the HIF-1 transcription factor complex, which is central to cellular oxygen sensing. In the same context, change in the structure of a protein is a known mechanism of stimulation of kinases, and regulatory proteins can be induced by protein-protein interactions.
In the context of gene regulation the present findings, demonstrating hBVR-haematin complex formation, and requirement for intact nuclear export/import signals for response of HO-1 to the metalloporphyrin inducer, define a previously unknown dimension of gene regulation by hBVR as an intracellular transporter of haematin; notably, haem is synthesized in the cytoplasm. It is also noteworthy that haematin activates the kinase activity of hBVR, whereas similar high concentrations of haematin inhibit the reductase activity [9] , perhaps by competing with biliverdin binding to the protein.
The availability of an hBVR mutant with impaired ATP binding (G17A mutant) afforded the opportunity to explore further the existence of a link between hBVR kinase activity and its function in haematin transport. The finding that in untreated living cells, the mobility of the mutant hBVR, as assessed by FCS in both cytoplasm and nucleus (Table 2) , was rather similar to that exhibited by the wild-type protein, while the haematin-mediated slowing of nuclear mobility was abolished for the G17A mutant, is indicative of an active (ATPdependent) process of haematin transport into the nucleus; thus it is not a diffusion process. This interpretation is not unprecedented and is consistent with reported findings that the phosphorylation status of β-catenin may influence its nuclear localization [50] . This interpretation is reinforced by the image shown in Figure 6 , which displays a perinuclear accumulation of the kinase-defective hBVR upon treatment with haematin. Furthermore, the availability of the disrupted potential haeminteracting domain mutant (C281A/C292A/C293A), and the use of peptides derived from the C-terminal domain, allowed for identification of a hBVR region that is involved in haematin binding. The mutation of the cysteine residues probably would not interfere with hBVR kinase activity. It is plausible that the inability of the cysteine mutant protein to form an S-S bond with a potential partner protein could disrupt the nuclear function of hBVR, as suggested by the observation ( Table 2 ) that, while the diffusion of the cysteine mutant is slowed in the nuclei of haematin-treated cells, it has a diffusion coefficient 50 % greater than that of wt hBVR.
Collectively, the FCS data support the likelihood of chromatin/DNA-hBVR interaction and possibly hBVR's involvement in the formation of protein-protein complexes in the nucleus. In addition, the data are consistent with the possibility that hBVR is an active ATP-dependent transporter of haematin within the cell, and therefore is a key component of the mechanism for haemregulated gene expression. Furthermore, this study has further proved the usefulness of the powerful FCS technique in finding new molecular mechanisms underlying hBVR mobility in living cells; a reliable examination of its behaviour in the presence and absence of ligands, and thereby has revealed new insights into functions of hBVR in the cell.
